Tumor M2-PK levels in haematological malignancies.
Circulating Tumor M2-PK serum levels were measured in 118 patients with various haematological malignancies. Using 17.5 U/ml as the cut-off level, elevated Tumor M2-PK concentrations were found in 7 out of 35 patients with acute myelocytic leukaemia, 17 out of 38 patients with chronic myelocytic leukaemia, 5 out of 18 patients with chronic lymphocytic leukaemia and in 6 out of 14 patients with acute lymphocytic leukaemia. Only 9 out of 195 healthy control individuals had Tumor M2-PK plasma levels above 17.5 U/ml. Serial determinations of Tumor M2-PK were performed in 3 patients with haematological malignancies during chemotherapy. Disease regression was associated with alternating Tumor M2-PK plasma levels. Thus, Tumor M2-PK is not a useful indicator of haematological malignancies. Moreover, serial Tumor M2-PK measurement may be insignificant in monitoring response to chemotherapy in these patients.
Oremek
G M
GM
Klinikum der Johann-Wolfgang Goethe-Universität Frankfurt, Zentrallabor-Zentrum Innere Medizin, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany.
Rox
St
S
Mitrou
P
P
Sapoutzis
N
N
Sauer-Eppel
H
H
D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000201:enzymology; D019337:Hematologic Neoplasms / Q000097:blood* / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D007680:Kidney Neoplasms / Q000097:blood / Q000201:enzymology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000201:enzymology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000201:enzymology; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000201:enzymology; D009101:Multiple Myeloma / Q000097:blood / Q000201:enzymology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000201:enzymology; D011770:Pyruvate Kinase / Q000097:blood*; D012016:Reference Values
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D011770:Pyruvate Kinase